Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Current Assets (2016 - 2026)

Phibro Animal Health has reported Current Assets over the past 13 years, most recently at $862.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 15.55% year-over-year to $862.2 million; the TTM value through Dec 2025 reached $862.2 million, up 15.55%, while the annual FY2025 figure was $810.6 million, 34.88% up from the prior year.
  • Current Assets for Q4 2025 was $862.2 million at Phibro Animal Health, up from $835.8 million in the prior quarter.
  • Over five years, Current Assets peaked at $862.2 million in Q4 2025 and troughed at $471.7 million in Q1 2021.
  • A 5-year average of $619.2 million and a median of $585.0 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: decreased 2.34% in 2024 and later surged 46.43% in 2025.
  • Year by year, Current Assets stood at $508.6 million in 2021, then rose by 14.37% to $581.7 million in 2022, then rose by 0.84% to $586.6 million in 2023, then increased by 27.2% to $746.2 million in 2024, then grew by 15.55% to $862.2 million in 2025.
  • Business Quant data shows Current Assets for PAHC at $862.2 million in Q4 2025, $835.8 million in Q3 2025, and $810.6 million in Q2 2025.